20160502-高盛-Initiating_India_coverage__Robust_growth_at_reasonable_valuations_98页_2mb

Summary of India Pharma Sector Analysis

Core Content

This document provides an in-depth analysis of the Indian pharmaceutical sector, focusing on its growth prospects, regulatory challenges, and competitive positioning in the global generic drug market. The report highlights the transition of Indian pharma from a "me too" generic strategy to a more sophisticated approach involving complex generics, biosimilars, and specialty drugs.

Main Points

Sector Growth and Valuation

• The Indian pharma sector is expected to grow revenues at a 14% CAGR (FY16E–FY20E), twice as fast as the global generic market.
• EBITDA and PAT growth are forecasted at 17% and 21% CAGR respectively.
• Valuations are currently undemanding, with a FY17 P/E of 21.5X, close to historical averages.

Regulatory Environment

• The sector has faced regulatory challenges, particularly from the US FDA, with 8 warning letters issued since October 2015.
• 3%–15% of Indian facilities have corrective action pending.
• The key deviations cited by the FDA include unauthorized computer access and inadequate electronic record-keeping.
• Despite these warnings, the report suggests the issues can be resolved through increased management focus, third-party assessments, and compliance culture development.

Product Strategy and Complexity

• Injectables are highlighted as a key area with early success and high growth potential due to low generic penetration.
• Specialty drugs have seen half of the top 15 opportunities approved under the Paragraph IV route.
• Biosimilars are still underdeveloped due to product development, regulatory, and financing challenges.
• The sector is increasing its exposure to complex generics, with 30% of US sales coming from these products in 2015.

M&A and Strategic Acquisitions

• Strategic M&A is a key growth driver, with recent deals such as Lupin's GAVIS acquisition and Cipla's Invagen deal.
• Sun Pharma's merger with Ranbaxy is expected to deliver revenue synergies and productivity gains, contributing to 13% sales growth.
• Sun Pharma is noted for its complex product portfolio and strong M&A firepower, with $3bn synergies expected by FY18E.

Competitive Positioning

• Aurobindo Pharma is highlighted as a top pick with a discount to sector valuation and high earnings growth.
• Sun Pharma is noted for its complex product portfolio and synergies.
• Cipla is rated as a sell, due to slow US market entry, domestic recovery, and valuation close to sector.
• Dr. Reddy's, Lupin, and Glenmark are rated neutral.

Key Information

Top Picks

• Aurobindo Pharma (CL-Buy): High earnings growth driven by a large product pipeline and complexity.
• Sun Pharma (Buy): Strong M&A capabilities and a complex product portfolio, with significant synergies from the Ranbaxy merger.
• Cipla (Sell): Laggard in US market entry and domestic recovery, with valuation close to sector.

Risks

• Regulatory compliance remains a key risk, particularly with FDA warnings.
• Channel consolidation and currency fluctuations are also mentioned as risks.

Valuation Approach

• The report forecasts earnings up to FY20E and applies an EV/EBITDA multiple of 15X on FY20E earnings.
• The 12-month target prices are calculated using the average WACC of 11%.

Table of Coverage Summary

• on our Conviction list.

Conclusion

The Indian pharmaceutical sector is well-positioned to regain global market share by leveraging complex generics, cost competitiveness, and strategic M&A. While regulatory challenges persist, they are seen as manageable rather than insurmountable. The report emphasizes the importance of product complexity and turnaround potential in identifying strong performers, with Sun Pharma and Aurobindo Pharma as top picks and Cipla as a sell.